SEP 16, 2014 10:00 AM PDT

Expanded clinical research opportunities for Crizotinib identified from an analysis of over 5,000 exomes

Speaker
  • Staff Scientist, Bioinformatics, Thermo Fisher Scientific
    Biography
      Dr. Eddy joined the Compendia Bioscience™ Translational Bioinformatics Services team, now part of Thermo Fisher Scientific, in July 2010. In his current position, Dr. Eddy provides oncology genomic solutions including but not limited to: identification and cataloging of actionable cancer driving genetic variants, assisting pharmaceutical partners in the identification/validation of novel drug targets, and the identification of potentially clinically relevant biomarkers using the Oncomine® Platform.  Prior to joining Thermo Fisher Scientific, he was employed as a scientist at Genstruct, Inc. in Cambridge, Massachusettes where he interrogated transcriptional regulatory networks to identify mechanisms of cancer progression, disease recurrence, drug-induced toxicity and drug resistance. He earned his doctorate from Carleton University in 1998 by characterizing the role that the PI3K/AKT and PPAR-gamma pathways in stress adaptation. He subsequently completed his postdoctoral studies at Boston University School of Medicine characterizing kinase signaling networks in breast cancer, and implicated IKBKE as having an oncogenic role in progression of the disease.

    Abstract
    Patients with chromosomal rearrangements resulting in fusion proteins are among the most responsive to published targeted therapy. For example, targeting of the EML4-ALK fusion in non-small cell lung cancer (NSCLC) with crizotinib has led to dramatic responses. While crizotinib is approved for use in EML4-ALK positive NSCLC for targeted inhibition of ALK, the drug also inhibits MET, MST1R (RON), ROS1, and more recently, has been reported to inhibit the ALK homolog LTK. To further understand the expanded therapeutic potential of crizotinib, a genomic survey to identify aberrations in ALK, MET, MST1R (RON), ROS1 and LTK was performed across >90,000 samples in the Oncomine Knowledgebase, including >7,000 samples subjected to full exome sequencing to identify known and novel fusion events. In this session, Dr. Eddy will reveal novel findings identified in this analysis including recurrent ALK fusions in colorectal adenocarcinoma, papillary renal cell carcinoma, thyroid gland carcinoma and sarcoma, as well as confirmation of the EML4-ALK fusion in lung adenocarcinoma. In this session, Dr. Eddy will highlight key findings of the analysis and provide an overall breakdown of molecular aberrations by cancer type.

    Show Resources
    You May Also Like
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    SEP 02, 2020 7:00 AM PDT
    C.E. CREDITS
    SEP 02, 2020 7:00 AM PDT
    DATE: September 2, 2020 TIME: 03:00pm PDT, 6:00pm EDT Spatial omics is an expanding collection of methods to examine biological molecules in their geographical context. By retaining the prec...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    Loading Comments...
    Show Resources
    Attendees
    • See more